<DOC>
	<DOCNO>NCT00879138</DOCNO>
	<brief_summary>A double blind , placebo-controlled , dose range study male age 65 , history nocturia . The study investigate pharmacodynamic outcome ( urine volume osmolality , circulate coagulation factor haemodynamics ) pharmacokinetics , single multiple oral dos VA106483 three dose level , condition control hydration .</brief_summary>
	<brief_title>Efficacy Safety VA106483 Elderly Males</brief_title>
	<detailed_description>VA106483 selective vasopressin V2 receptor agonist currently development treatment nocturia male . This study examine pharmacological action VA106483 marker clinical efficacy ( urine volume osmolality ) safety marker ( coagulation factor haemodynamics ) . The study also assess pharmacokinetics study population . The study design include cross-over parallel phase pharmacodynamic pharmacokinetic parameter assess follow single repeat dosing . Three dose level give .</detailed_description>
	<mesh_term>Nocturia</mesh_term>
	<criteria>Males 65 year history nocturia Any clinically significant concomitant medical disease , condition abnormal laboratory test result Participation clinical study within 30 day Intake nonprescription medication within 14 day</criteria>
	<gender>Male</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>